Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2 nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA.

Details of presentation:

Format: Fireside chat

Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer

Date and Time: November 10, 2025, at 4:00 p.m. ET

The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage .

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit tenaxthera.com . Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Contact:

Investor and Media:

Argot Partners [email protected]